# Lindus

> Lindus, founded in 2021 as Lindus Health, built an integrated clinical-trial platform and fixed-price CRO service. After Curavit acquired its CRO assets in August 2026, Lindus Therapeutics focuses on in-licensing clinical-stage medicines and developing them with its own operational team, Citrus trial software and SOURCE asset-selection system.

- **Founded:** 2021
- **Headquarters:** Boston, United States
- **Founders:** Meri Beckwith (Co-Founder and CEO), Michael Young (Co-Founder), Nik Haldimann (Co-Founder; founding CTO)
- **Products:** Citrus, SOURCE, In-licensed therapeutic asset development, End-to-end CRO services (historical)
- **Notable:** Raised a US$55 million Series B in January 2025; the company reports over US$80 million raised overall., Reports 45 completed end-to-end trials as the foundation of its current development platform., Won the 2025 Fierce CRO Award for Outstanding Patient Recruitment and Retention.

## Products & services

- **Citrus** — Proprietary trial operating system connecting participant identification, electronic consent, data capture, participant-reported outcomes, trial management and monitoring. Retained as part of the therapeutic-development platform.
- **SOURCE** — AI-assisted asset-identification system; the company reports a queryable registry of more than 60,000 drug assets linking trials, biology, indications and intellectual property.
- **In-licensed therapeutic asset development** — Selects clinical-stage medicines and advances them toward clinical value inflection points or approval using internal development functions.
- **End-to-end CRO services (historical)** — Trial design, recruitment, execution, monitoring, data management and reporting, sold through fixed-price study contracts with milestone payments. Curavit acquired the CRO assets in August 2026.

## Achievements

- Raised a US$55 million Series B in January 2025; the company reports over US$80 million raised overall.
- Reports 45 completed end-to-end trials as the foundation of its current development platform.
- Won the 2025 Fierce CRO Award for Outstanding Patient Recruitment and Retention.
- CTTI documented its use of AACT for feasibility prediction, protocol drafting and outcome standardization.
- CRO assets acquired by Curavit in August 2026.

## Latest updates

- **2026-08** — Curavit announced acquisition of Lindus Health’s CRO assets on August 18; Lindus shifted toward its own therapeutic pipeline.
- **2026-09** — Gillian Cannon joined the board as a non-executive director on September 8.
- **2026-09** — CEO Meri Beckwith published Biopharma in the age of AI on September 30, describing the rationale for asset selection and integrated clinical development.

## Links

- Website: https://www.lindustx.com/
- LinkedIn: https://www.linkedin.com/company/lindushealth/
- Twitter/X: https://x.com/LindusTx
- YouTube: https://www.youtube.com/@LindusTherapeutics
- Facebook: https://www.facebook.com/LindusTherapeutics/

---

Profile page: https://yespress.io/lindus
Published by YesPress — https://yespress.io
Last updated: 2026-10-04